Table 1 Pathological diagnosis of all patients.
From: Differentiation of malignant cervical lymphadenopathy by dual-energy CT: a preliminary analysis
Diagnosis | Case number (n = 92) |
|---|---|
Thyroid carcinoma | 18 (19.57%) |
Papillary carcinoma | 18 (19.57%) |
Salivary carcinoma | 9 (9.78%) |
Adenoid cystic carcinoma | 2 (2.17%) |
Mucoepidermoid carcinoma | 1 (1.09%) |
Epithelial-myoepithelial carcinoma | 1 (1.09%) |
Nonspecific adenocarcinoma | 1 (1.09%) |
Metastasizing pleomorphic adenoma | 1 (1.09%) |
Ductal adenocarcinoma | 2 (2.17)% |
Basal cell adenocarcinoma | 1 (1.09%) |
SCC | 36 (39.13%) |
Nasopharyngeal carcinoma | 13 (14.13%) |
Tonsillar carcinoma | 1 (1.09%) |
Pharyngeal carcinoma | 8 (8.70%) |
Hypopharyngeal carcinoma | 4 (4.35%) |
Tongue carcinoma | 4 (4.35%) |
Esophageal carcinoma | 2 (2.17%) |
Oropharyngeal carcinoma | 4 (4.35%) |
Lymphoma | 29 (31.52%) |
Mantle cell lymphoma | 1 (1.09%) |
Follicular Lymphoma | 4 (4.35%) |
Diffuse large B-cell lymphoma | 14 (15.22%) |
Peripheral T-cell lymphoma | 1 (1.09%) |
Nodular sclerosis Hodgkin lymphoma | 3 (3.26%) |
Mixed cellularity Hodgkin lymphoma | 2 (2.17%) |
Lymphocyte-rich Hodgkin lymphoma | 1 (1.09%) |
Lymphocyte depletion Hodgkin lymphoma | 1 (1.09%) |
Extranodal nasal-type natural killer/T-cell lymphoma | 1 (1.09%) |
Peripheral T-cell lymphoma | 1 (1.09%) |
